(Bloomberg) — A decade ago, Joe Jimenez was peddling ketchup and baked beans. Now he's using Microsoft Corp.'s gaming technology and embedding Google Inc. sensors in contact lenses to reinvent the world's biggest drugmaker.

As Novartis AG's chief executive, Jimenez is barreling down untested paths at the frontier of biology and digital technology to prepare for a future in which the use of smartphones and other digital devices to monitor health will be the key to getting paid.

Jimenez is also taking an axe to the empire built by his flamboyant predecessor, Daniel Vasella, with a complex asset swap worth more than $30 billion that closed this month. By offloading vaccines and adding cancer drugs, the 55-year-old former competitive swimmer is preparing Novartis for the loss of patents on medicines that make up a fifth of its sales.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.